LRUSF Financials 07/16/2014 05:01:09 Lorus Therap

LRUSF Financials 07/16/2014 05:01:09
Lorus Therapeutics, Inc.
Period Ending May 31, 2013 May 31, 2012 May 31, 2011 Jun 01, 2010
Total Revenue - - - 125
Cost of Revenue - - - -
Gross Profit - - - 125
Operating Expenses
Research and Development 3,209 2,095 2,599 2,399
Sales, General and Admin. 2,198 2,346 2,498 2,993
Non-Recurring Items - - - -
Other - - - 82
Operating Income (5,408) (4,441) (5,097) (5,348)
Income From Continuing Operations
Add'l Income/Expense Items 29 6 14 10,432
Earnings Before Interest and Tax (5,378) (4,436) (5,083) (5,405)
Interest Expense 6 19 73 51
Earnings Before Tax (5,384) (4,455) (5,156) (5,456)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - 48
Net Income Cont. Operations (5,384) (4,455) (5,156) 5,080
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (5,384) (4,455) (5,156) 5,080
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (5,384) (4,455) (5,156) 5,080